<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02189967</url>
  </required_header>
  <id_info>
    <org_study_id>STR-PORTAF-2014</org_study_id>
    <nct_id>NCT02189967</nct_id>
  </id_info>
  <brief_title>Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation</brief_title>
  <official_title>Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Consortium for Translational Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Radiation Research in Oncology Dresden/Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiation Oncology Working Group of the German Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized multicentric phase II study it will be investigated whether an accelerated&#xD;
      postoperative radiotherapy with photons or protons (7 fractions per week, 2 Gy single dose)&#xD;
      may improve locoregional tumour control in non-small cell lung cancer (NSCLC) in comparison&#xD;
      to conventional fractionation (5 fractions per week, 2 Gy single dose).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized multicentric trial. Within this study an accelerated irradiation&#xD;
      schedule (7 fractions per week, 2 Gy single dose) will be compared with the currently used&#xD;
      conventional fractionation schedule (5 fractions per week, 2 Gy single dose) for&#xD;
      postoperative radiotherapy with photons or protons in patients with NSCLC. The primary&#xD;
      endpoint is locoregional tumour control after 36 months. Secondary endpoints are overall&#xD;
      survival of patients, local recurrence-free and distant metastases-free survival after 36&#xD;
      months, acute and late toxicity as well as quality of life for both treatment methods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Actual">July 2020</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of local tumor control</measure>
    <time_frame>36 months after therapy</time_frame>
    <description>Local tumor control will be assessed by appropriate non-invasive (CT or PET-CT) and if necessary invasive examination methods (bronchoscopy with biopsy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>36 months after therapy</time_frame>
    <description>Follow-up visits should be continued in all patients until death. Otherwise patients will be censored with date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local recurrence-free survival</measure>
    <time_frame>36 months after therapy</time_frame>
    <description>Local-recurrences will be assessed by appropriate non-invasive (CT or PET-CT) and if necessary invasive examination methods (bronchoscopy with biopsy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>Comparison after 20, 50, 100 and 200 patients have been treated. This number of patients is expected to be included after 6, 12, 18 and 40 months.</time_frame>
    <description>The occurrence of acute side effects (up to 90 days after start of treatment) will be recorded and documented based on CTCAE 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>36 months after therapy</time_frame>
    <description>The assessment of quality of life is carried out using the established EORTC QLQ-C30 questionnaire and the additional lung module QLQ-LC13. Quality of life will be documented immediately before the start of therapy, after completion of postoperative radiotherapy and at every follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant metastases-free survival</measure>
    <time_frame>36 months after therapy</time_frame>
    <description>Distant metastases will be assessed by PET-CT or abdominal sonography and chest x-ray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late toxicity</measure>
    <time_frame>Comparison after 20, 50, 100 and 200 patients have been treated. This number of patients is expected to be included after 6, 12, 18 and 40 months.</time_frame>
    <description>The occurrence of late side effects will be recorded and documented based on CTCAE 4.0 after every follow-up visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>conventional fractionation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>radiotherapy with conventional fractionation (5 x 2Gy per week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>accelerated fraction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>radiotherapy with accelerated fraction (7 x 2 Gy per week)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>conventional fractionation</intervention_name>
    <description>In this treatment arm patients will receive radiotherapy with the currently used conventional fractionation schedule i.e. 5 fractions per week, 2 Gy single dose.</description>
    <arm_group_label>conventional fractionation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>accelerated fraction</intervention_name>
    <description>In this treatment arm patients will receive radiotherapy with an accelerated fractionation schedule i.e. 7 fractions per week, 2 Gy single dose.</description>
    <arm_group_label>accelerated fraction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed non-small cell lung cancer&#xD;
&#xD;
          -  previous tumor resection with curative intention&#xD;
&#xD;
          -  postoperative indication for irradiation (&gt; pN1 and/ or R1)&#xD;
&#xD;
          -  R2-resection or recurrence postoperative/after adjuvant chemotherapy diagnosed by the&#xD;
             restaging-imaging&#xD;
&#xD;
          -  exclusion of distant metastases (M0)&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
          -  good general condition (ECOG performance status 0 or 1)&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  appropriate compliance to ensure close follow-up&#xD;
&#xD;
          -  women of childbearing age: adequate contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed small cell lung cancer&#xD;
&#xD;
          -  distant metastases&#xD;
&#xD;
          -  no written informed consent or lack of cooperation relating to therapy or follow-up&#xD;
&#xD;
          -  previous (&lt; 5 years) or concomitant other malignant disease (exception: malignant&#xD;
             disease, which is very likely healed and not influenced therapy or follow up of the&#xD;
             non-small cell lung cancer, e.g. carcinoma in-situ, basaliomas, very early skin&#xD;
             cancers)&#xD;
&#xD;
          -  for proton therapy: heart pacemaker&#xD;
&#xD;
          -  previous radiotherapy of the thorax or lower neck region&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  participation in another intervention study or not completed follow-up of a&#xD;
             intervention study. Exceptions are psychological studies, supportive or observation&#xD;
             studies, the previous therapy of non-small cell lung cancer is in accordance with the&#xD;
             guideline and the participation in radiotherapy studies is not excluded in the trial&#xD;
             protocol of the previous study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Bütof, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dresden University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden, Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Strahlentherapie Hamburg-Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes, Department of Radiotherapy and Radiation Oncology</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München,Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Technische Universität München, Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Stuttgart, Department of Radiotherapy and Palliative Medicine</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>Tübingen</city>
        <zip>72016</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ MSW; Warmia &amp; Mazury Oncology Center; Warmia &amp; Mazury Medical University</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 22, 2014</study_first_submitted>
  <study_first_submitted_qc>July 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2014</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Dr. Rebecca Bütof</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>accelerated fractionation</keyword>
  <keyword>conventional fractionation</keyword>
  <keyword>postoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

